Literature DB >> 22106415

Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis.

Andrey Kazakov1, Patrick Müller, Philippe Jagoda, Alexander Semenov, Michael Böhm, Ulrich Laufs.   

Abstract

AIMS: The endothelial nitric oxide synthase (eNOS) regulates the mobilization and function of endothelial progenitor cells (EPC). We hypothesized that eNOS of the bone marrow (BM) affects cardiac remodelling during myocardial hypertrophy via the regulation of BM-derived vascular progenitor cells. METHODS AND
RESULTS: Ten-week-old male C57/Bl6 wild-type (WT) and eNOS mice (eNOS(-/-)) were subjected to transverse aortic constriction (TAC, 360 μm, 35 days) or sham operation inducing cardiac hypertrophy and increasing the numbers of Ki67+ cardiomyocytes in both strains. Myocardial fibrosis was more pronounced in eNOS(-/-) TAC (3.4 ± 0.4 vs. 2.1 ± 0.2% in WT-TAC, P < 0.05). TAC up-regulated the number of EPCs in the peripheral blood and in the BM in WT but not in eNOS(-/-). Baseline migratory capacity of EPCs was lower in eNOS(-/-) and was not raised by TAC in either strain. To test the role of eNOS in the BM during pressure overload, strain-mismatched (WT/eNOS(-/-); eNOS(-/-)/WT) and strain-matched (WT/WT; eNOS(-/-)/eNOS(-/-)) BM transplantations (BMTs) were performed. Cardiac hypertrophy was most pronounced in WT/eNOS(-/-) TAC. Strain-mismatched BMT of eNOS(-/-) BM deteriorated and of WT BM ameliorated cardiac fibrosis, capillary density, the numbers of EPCs in the peripheral blood and in the BM, and their migratory capacity in pressure overload. Following transplantation of green fluorescent protein (GFP)-positive BM, TAC increased the number of BM-derived podocalyxin(pos)GFP(pos) endothelial cells in both strains.
CONCLUSION: eNOS of the BM plays a key role for amelioration of cardiac hypertrophy, capillary density, and fibrosis during increased afterload.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22106415     DOI: 10.1093/cvr/cvr305

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

1.  Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.

Authors:  David M Charytan; Robert Padera; Alexander M Helfand; Michael Zeisberg; Xingbo Xu; Xiaopeng Liu; Jonathan Himmelfarb; Angeles Cinelli; Raghu Kalluri; Elisabeth M Zeisberg
Journal:  Int J Cardiol       Date:  2014-07-06       Impact factor: 4.164

Review 2.  Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Authors:  David Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

Review 3.  AMP-activated protein kinase in the control of cardiac metabolism and remodeling.

Authors:  Sandrine Horman; Christophe Beauloye; Jean-Louis Vanoverschelde; Luc Bertrand
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 4.  Role of Nitric Oxide in the Cardiovascular and Renal Systems.

Authors:  Ashfaq Ahmad; Sara K Dempsey; Zdravka Daneva; Maleeha Azam; Ningjun Li; Pin-Lan Li; Joseph K Ritter
Journal:  Int J Mol Sci       Date:  2018-09-03       Impact factor: 5.923

Review 5.  Nitric oxide synthases in heart failure.

Authors:  Ricardo Carnicer; Mark J Crabtree; Vidhya Sivakumaran; Barbara Casadei; David A Kass
Journal:  Antioxid Redox Signal       Date:  2012-09-20       Impact factor: 8.401

Review 6.  Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives.

Authors:  Maria E Marketou; Fragiskos Parthenakis; Panos E Vardas
Journal:  Stem Cells Int       Date:  2015-12-20       Impact factor: 5.443

7.  Distinct Anti-Fibrotic Effects of Exosomes Derived from Endothelial Colony-Forming Cells Cultured Under Normoxia and Hypoxia.

Authors:  WenHao Liu; HaiFeng Zhang; JingTing Mai; ZhiTeng Chen; TuCheng Huang; ShaoHua Wang; YangXin Chen; JingFeng Wang
Journal:  Med Sci Monit       Date:  2018-09-05

Review 8.  Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.